Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Clinical Implications Of Severe Isolated Hepatic Gvhd Post-DLI

Ting Yang, M.D., Ph.D., Xu Huang, M.D., Xiaofeng Luo, M.D., Xiaohong Yuan, M.D., Danhui Fu, Zhizhe Chen, Prof., Jianda Hu, MD

Blood (2013) 122 (21): 5481.

https://doi.org/10.1182/blood.V122.21.5481.5481

Published: 2013

Journal Articles

Flamsa-RIC Sequential Regimen in High Risk CR1 AML Patients: Preliminary Results From a Pilot Study

Blood (2012) 120 (21): 4549.

https://doi.org/10.1182/blood.V120.21.4549.4549

Published: 2012

Journal Articles

Monitoring the Antileukemic Immune Response with an Active Specific Immunization Strategy

Ting Yang, M.D., Ph.D., Zhizhe Chen, Hans-Jochem Kolb, MD, Raymund Buhmann, MD

Blood (2012) 120 (21): 4354.

https://doi.org/10.1182/blood.V120.21.4354.4354

Published: 2012

Journal Articles

Treatment of Acute Graft-Versus-Host Disease by Means of Multipotent Mesenchymal Stromal Cells: Role of Immunomodulating Soluble Factors Expressed by These Cells in Vitro

Natalia A. Petinaty, Larisa A. Kuzmina, Irina N. Shipounova, Oxana A Zhironkina, Alexey Bigildeev, Lidya S. Lubimova, Elena O. Gribanova, Elena N Parovichnikova, Nina I. Drize, Valeri G Savchenko

Blood (2011) 118 (21): 4554.

https://doi.org/10.1182/blood.V118.21.4554.4554

Published: 2011

Journal Articles

Outcome of High-Risk and Refractory AML/MDS Patients Receiving a FLAMSA Sequential Chemotherapy Regimen Followed by Reduced-Intensity Conditioning (RIC) and Allogeneic Hematopoeitic Stem Cell Transplantation (allo-HSCT)

Marie Y. Detrait, MD, Patrice Chevallier, MD, PhD, Mohamad Sobh, Pharm.M., Thierry Guillaume, Xavier Thomas, MD, PhD, Stephane Morisset, Stat., Nathalie Tedone, CRA, Jacques Delaunay, MD, Franck E. Nicolini, MD, PhD, Helene Labussiere, MD, Sophie Ducastelle, MD, Jihane Fattoum, MD, PhD, Fiorenza Barraco, MD, Giovanna Cannas, MD, Youcef Chelghoum, MD, Mohamad Mohty, Mauricette Michallet

Blood (2011) 118 (21): 1957.

https://doi.org/10.1182/blood.V118.21.1957.1957

Published: 2011

Journal Articles

Long Term Follow-up of Patients Treated with mTOR Inhibitors for Severe Chronic Gvhd Following Allogeneic Stem Cell Transplantation.

Michael Schleuning, Dirk Judith, Irena Burlakova, Zuzanna Jedlickova, Mansour Heshmat, Herrad Baurmann, Rainer Schwerdtfeger

Blood (2009) 114 (22): 2254.

https://doi.org/10.1182/blood.V114.22.2254.2254

Published: 2009

Journal Articles

Long-Term Results of Donor Lymphocyte Transfusions for the Treatment of Relapse After Allogeneic Transplantation for Chronic Myelogenous Leukemia - Is There a Role for Immunotherapy in CML?.

Hans-Jochem Kolb, Dagmar Bund, PhD, Helga Schmetzer, PhD, Prof, Christoph Schmid, MD, PhD, Raymund Buhmann, MD, Johanna Tischer, MD, Georg Ledderose, MD

Blood (2009) 114 (22): 2258.

https://doi.org/10.1182/blood.V114.22.2258.2258

Published: 2009

Journal Articles

Graft-versus-leukemia effects of transplantation and donor lymphocytes

Hans-Jochem Kolb

Blood (2008) 112 (12): 4371–4383.

https://doi.org/10.1182/blood-2008-03-077974

Published: 2008

Journal Articles

Clinical Relevance of Minimal Residual Disease and Chimerism for the Detection of Relapse after Hematopoietic Stem Cell Transplantation

Bernd Gruhn, Juliane Sanft, Nadine Pfaffendorf, Ilona Wolff, Dietlinde Fuchs, Felix Zintl, James Beck

Blood (2008) 112 (11): 338.

https://doi.org/10.1182/blood.V112.11.338.338

Published: 2008

Journal Articles

Graft-Versus-Host Tolerance in Dogs Following T-Cell Depleted Bone Marrow Transplantation with Absorbed ATG or CD6-Antibody.

Julia Zorn, Hans Jochem Kolb, MD

Blood (2008) 112 (11): 2338.

https://doi.org/10.1182/blood.V112.11.2338.2338

Published: 2008

Journal Articles

Long Term Follow-up and Matched Pair Analysis of Adjuvant Donor Lymphocyte Transfusions Following Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for High-Risk AML.

Michael Schleuning, Christoph Schmid, Christian Koenecke, Bernd Hertenstein, Herrad Baurmann, Rainer Schwerdtfeger, Hans-Jochem Kolb

Blood (2008) 112 (11): 2142.

https://doi.org/10.1182/blood.V112.11.2142.2142

Published: 2008

Journal Articles

Treatment of Relapse of AML and MDS after Allogeneic Stem Cell Transplantation Using Low-Dose Chemotherapy, Donor PBSC and GM-CSF: Final Results from a Prospective, Multicenter Phase II Trial by the German Cooperative Transplant Group.

Christoph Schmid, MD, Johanna Tischer, MD, Matthias Stelljes, MD, Michael Schleuning, MD, Rainer Schwerdtfeger, MD, Ute Hegenbart, MD, Joerg Schubert, MD, Wichard Vogel, MD, Berd Gruhn, MD, Christiane Lallinger, Georg Ledderose, MD, Martin Bornhaeuser, MD, Joachim Kienast, MD, Hans-Jochem Kolb, MD

Blood (2007) 110 (11): 1651.

https://doi.org/10.1182/blood.V110.11.1651.1651

Published: 2007

Journal Articles

Immune Effects of Imatinib in Chronic Myelogenous Leukemia In Vitro.

Dagmar Bund, PhD, Raymund Buhmann, MD, Hans-Jochem Kolb, MD, PhD

Blood (2007) 110 (11): 2956.

https://doi.org/10.1182/blood.V110.11.2956.2956

Published: 2007

Journal Articles

Allogeneic Stem Cell Transplantation for MDS and sAML Following Reduced Intensity Conditioning and Preemptive Donor Lymphocyte Transfusion.

Hans-Jochem Kolb, MD, PhD, Christoph Schmid, MD, Johanna Tischer, MD, Andreas Haussmann, MD, Andreas Rank, MD, Michael Schleuning, MD, Georg Ledderose, MD

Blood (2006) 108 (11): 324.

https://doi.org/10.1182/blood.V108.11.324.324

Published: 2006

Journal Articles

Hematopietic Cell Transplantation after a Low-Dose, Total-Body Irradiation Based Regimen in Elderly Patients with AML: A Multicenter, Multinational, Prospective HOVON/SAKK/OSHO Study.

Dietger Niederwieser, MD, Jan Cornelissen, MD, Haifa-Kathrin Al-Ali, MD, Leo Verdonck, MD, Rainer Krahl, MD, Alois Gratwohl, MD, Claudia Nehring, MD, Cornelia Becker, MD, Wolfram Poenisch, MD, Thoralf Lange, MD, Rainer Storb, MD, Bob Lowenberg, MD

Blood (2006) 108 (11): 321.

https://doi.org/10.1182/blood.V108.11.321.321

Published: 2006

Journal Articles

Improved Survival with Adjuvant Donor Lymphocyte Transfusions Following Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for High-Risk AML.

Michael Schleuning, Christoph Schmid, Christian Koenecke, Bernd Hertenstein, Herrad Baurmann, Rainer Schwerdtfeger, PD, Hans-Jochem Kolb

Blood (2006) 108 (11): 3661.

https://doi.org/10.1182/blood.V108.11.3661.3661

Published: 2006

Journal Articles

Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation

Christoph Schmid, Michael Schleuning, Rainer Schwerdtfeger, Bernd Hertenstein, Eva Mischak-Weissinger, Donald Bunjes, Stephanie v. Harsdorf, Christoph Scheid, Udo Holtick, Hildegard Greinix, Felix Keil, Barbara Schneider, Michael Sandherr, Gesine Bug, Johanna Tischer, Georg Ledderose, Michael Hallek, Wolfgang Hiddemann, Hans-Jochem Kolb

Blood (2006) 108 (3): 1092–1099.

https://doi.org/10.1182/blood-2005-10-4165

Published: 2006

Journal Articles

Adoptive Immunotherapy of p53-Mutated B-CLL with a Trifunctional Antibody (Anti-CD3 x Anti-CD20) and Allogeneic Donor Lymphocyte Transfusion.

Raymund Buhmann, MD, Michael Stanglmaier, PhD, Belinda Simoes, MD, Ting Yang, MD, Peter Ruf, PhD, Horst Lindhofer, PhD, Hans-Jochem Kolb, MD, PhD

Blood (2005) 106 (11): 4823.

https://doi.org/10.1182/blood.V106.11.4823.4823

Published: 2005

Journal Articles

Donor Lymphocyte Transfusion (DLT) in the Treatment of Relapsed CML after Allogeneic PBSCT - A Retrospective Analysis of 346 Patients by the EBMT Chronic Leukemia Working Party.

Christoph Schmid, MD, Anja v. Biezen, Kimmo Porkka, MD, Yves Chalandon, MD, Alvaro Urbano, MD, Eduardo Olavarria, MD, Theo de Witte, MD, Bernd Hertenstein, MD, Wiliam Archese, MD, Richard Clark, MD, Hans-Jochem Kolb, MD, Dietger Niederwieser, MD, Cesare Guglielmi, MD

Blood (2005) 106 (11): 704.

https://doi.org/10.1182/blood.V106.11.704.704

Published: 2005

Journal Articles

Retrospective Comparison of Using or Not Using Donor Lymphocyte Transfusion in the Treatment of Hematological Relapse after Allogeneic Stem Cell Transplantation in 489 Adults with Acute Myeloid Leukemia.

Christoph Schmid, MD, Myriam Labopin, MD, Juergen Finke, MD, Gerhard Ehninger, MD, Olle Ringden, MD, Dietger Niederwieser, MD, Ioanna Sakellari, MD, Alvaro Urbano-Ispizua, MD, Tapani Ruutu, MD, Gunham Gurman, MD, Richard E. Clarke, MD, Norbert Gorin, MD, Emmanuelle Polge, Loic Fouillard, MD, Francesco Frassoni, MD, Hans-Jochem Kolb, MD, Vanderson Rocha for the EMBT ALWP

Blood (2004) 104 (11): 298.

https://doi.org/10.1182/blood.V104.11.298.298

Published: 2004

NARROW

Clinical Implications Of Severe Isolated Hepatic Gvhd Post-DLI

Flamsa-RIC Sequential Regimen in High Risk CR1 AML Patients: Preliminary Results From a Pilot Study

Monitoring the Antileukemic Immune Response with an Active Specific Immunization Strategy

Treatment of Acute Graft-Versus-Host Disease by Means of Multipotent Mesenchymal Stromal Cells: Role of Immunomodulating Soluble Factors Expressed by These Cells in Vitro

Outcome of High-Risk and Refractory AML/MDS Patients Receiving a FLAMSA Sequential Chemotherapy Regimen Followed by Reduced-Intensity Conditioning (RIC) and Allogeneic Hematopoeitic Stem Cell Transplantation (allo-HSCT)

Long Term Follow-up of Patients Treated with mTOR Inhibitors for Severe Chronic Gvhd Following Allogeneic Stem Cell Transplantation.

Long-Term Results of Donor Lymphocyte Transfusions for the Treatment of Relapse After Allogeneic Transplantation for Chronic Myelogenous Leukemia - Is There a Role for Immunotherapy in CML?.

Graft-versus-leukemia effects of transplantation and donor lymphocytes

Clinical Relevance of Minimal Residual Disease and Chimerism for the Detection of Relapse after Hematopoietic Stem Cell Transplantation

Graft-Versus-Host Tolerance in Dogs Following T-Cell Depleted Bone Marrow Transplantation with Absorbed ATG or CD6-Antibody.

Long Term Follow-up and Matched Pair Analysis of Adjuvant Donor Lymphocyte Transfusions Following Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for High-Risk AML.

Treatment of Relapse of AML and MDS after Allogeneic Stem Cell Transplantation Using Low-Dose Chemotherapy, Donor PBSC and GM-CSF: Final Results from a Prospective, Multicenter Phase II Trial by the German Cooperative Transplant Group.

Immune Effects of Imatinib in Chronic Myelogenous Leukemia In Vitro.

Allogeneic Stem Cell Transplantation for MDS and sAML Following Reduced Intensity Conditioning and Preemptive Donor Lymphocyte Transfusion.

Hematopietic Cell Transplantation after a Low-Dose, Total-Body Irradiation Based Regimen in Elderly Patients with AML: A Multicenter, Multinational, Prospective HOVON/SAKK/OSHO Study.

Improved Survival with Adjuvant Donor Lymphocyte Transfusions Following Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for High-Risk AML.

Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation

Adoptive Immunotherapy of p53-Mutated B-CLL with a Trifunctional Antibody (Anti-CD3 x Anti-CD20) and Allogeneic Donor Lymphocyte Transfusion.

Donor Lymphocyte Transfusion (DLT) in the Treatment of Relapsed CML after Allogeneic PBSCT - A Retrospective Analysis of 346 Patients by the EBMT Chronic Leukemia Working Party.

Retrospective Comparison of Using or Not Using Donor Lymphocyte Transfusion in the Treatment of Hematological Relapse after Allogeneic Stem Cell Transplantation in 489 Adults with Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only